Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Печать: 0278-940X
ISSN Онлайн: 1943-619X

Выпуски:
Том 47, 2019 Том 46, 2018 Том 45, 2017 Том 44, 2016 Том 43, 2015 Том 42, 2014 Том 41, 2013 Том 40, 2012 Том 39, 2011 Том 38, 2010 Том 37, 2009 Том 36, 2008 Том 35, 2007 Том 34, 2006 Том 33, 2005 Том 32, 2004 Том 31, 2003 Том 30, 2002 Том 29, 2001 Том 28, 2000 Том 27, 1999 Том 26, 1998 Том 25, 1997 Том 24, 1996 Том 23, 1995

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.v38.i2.30
pages 143-156

Molecular Networks in Drug Discovery

John Kenneth Morrow
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Longzhang Tian
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Shuxing Zhang
The Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Краткое описание

Despite the dramatic increase of global spending on drug discovery and development, the approval rate for new drugs is declining, due chiefly to toxicity and undesirable side effects. Simultaneously, the growth of available biomedical data in the postgenomic era has provided fresh insight into the nature of redundant and compensatory drug-target pathways. This stagnation in drug approval can be overcome by the novel concept of polypharmacology, which is built on the fundamental concept that drugs modulate multiple targets. Polypharmacology can be studied with molecular networks that integrate multidisciplinary concepts including cheminformatics, bioinformatics, and systems biology. In silico techniques such as structure- and ligand-based approaches can be employed to study molecular networks and reduce costs by predicting adverse drug reactions and toxicity in the early stage of drug development. By amalgamating strides in this informatics-driven era, designing polypharmacological drugs with molecular network technology exemplifies the next generation of therapeutics with less of-target properties and toxicity. In this review, we will first describe the challenges in drug discovery, and showcase successes using multitarget drugs toward diseases such as cancer and mood disorders. We will then focus on recent development of in silico polypharmacology predictions. Finally, our technologies in molecular network analysis will be presented.


Articles with similar content:

From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.15, 1998, issue 2
Alain P. Rolland
Drug-Polymer Conjugates Containing Acid-Cleavable Bonds
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.16, 1999, issue 3
Mark Thomas Schutte, Felix Kratz, Ulrich Beyer
Current Nanotechnological Strategies for an Effective Delivery of Drugs in Treatment of Periodontal Disease
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 2
Goutam Rath, Tarun Garg, Amit Kumar Goyal, Gagandeep Goyal
Potential Approaches for Drug Delivery to the Brain: Past, Present, and Future
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 3
Vandana Soni, Piush Khare, Anekant Jain, Arvind Gulbake, Sanjay Kumar Jain
Microsponges: A Pioneering Tool for Biomedical Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 1
Amit Verma, Ankit Jain, Pooja Hurkat, Amrita Kumari, Sanjay Kumar Jain